Vascular-targeting antioxidant therapy in a model of hypertension and stroke

Journal of Cardiovascular Pharmacology

Volumn 56, Issue 6, 2010, Pages 642-650

  Greig, Jenny A ^a   Shirley, Rachel ^a   Graham, Delyth ^a   Denby, Laura ^a   Dominiczak, Anna F ^a   Work, Lorraine M ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Antioxidant peptide; Hypertension; NAD(P)H oxidase; Vascular targeting

Indexed keywords

ANTIOXIDANT; CRPPR GP91DS; CSGMARTKC GP91DS; GLYCOPROTEIN GP 91; GP91DS; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG EFFECT; EUTHANASIA; HYPERTENSION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN TARGETING; RAT; STROKE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MICE; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; STROKE;

EID: 78751645815     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181f8f19f     Document Type: Article

References (43)

1. Berry C, Brosnan MJ, Fennell J, et al. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens. 2001;10:247-255.
2. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
3. Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997; 20(Suppl 2):II-11-II-17.
4. Rey FE, Li XC, Carretero OA, et al. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation: role of gp91(phox). Circulation. 2002;106:2497-2502.
5. Gorlach A, Brandes RP, Nguyen K, et al. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26-32.
6. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593.
7. Mollnau H,Wendt M, Szocs K, et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res. 2002;90:E58-E65.
8. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000;101:948-954.
9. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
10. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
11. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
12. Lassegue B, Sorescu D, Szocs K, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001;88:888-894.
13. Sorescu D, Weiss D, Lassegue B, et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002;105:1429-1435.
14. Rey FE, Cifuentes ME, Kiarash A, et al. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res. 2001;89:408-414.
15. Zhou MS, Hernandez Schulman I, Pagano PJ, et al. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension. 2006;47:81-86.
16. Wang HD, Xu S, Johns DG, et al. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res. 2001;88:947-953.
17. Zhang L, Hoffman JA, Ruoslahti E. Molecular profiling of heart endothelial cells. Circulation. 2005;112:1601-1611.
18. Davidson AO, Schork N, Jaques BC, et al. Blood pressure in genetically hypertensive rats. Influence of the Y chromosome. Hypertension. 1995; 26:452-459.
19. Clark JS, Jeffs B, Davidson AO, et al. Quantitative trait loci in genetically hypertensive rats. Possible sex specificity. Hypertension. 1996;28:898-906.
20. McIntyre M, Hamilton CA, Rees DD, et al. Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension. 1997;30:1517-1524.
21. Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54:322-328.
22. Alexander MY, Brosnan MJ, Hamilton CA, et al. Gene transfer of endothelial nitric oxide synthase improves nitric oxide-dependent endothelial function in a hypertensive rat model. Cardiovasc Res. 1999;43:798-807.
23. Alexander MY, Brosnan MJ, Hamilton CA, et al. Gene transfer of endothelial nitric oxide synthase but not Cu/Zn superoxide dismutase restores nitric oxide availability in the SHRSP. Cardiovasc Res. 2000;47: 609-617.
24. Dowell FJ, Martin W, Dominiczak AF, et al. Decreased basal despite enhanced agonist-stimulated effects of nitric oxide in 12-week-old strokeprone spontaneously hypertensive rat. Eur J Pharmacol. 1999;379: 175-182.
25. Fennell JP, Brosnan MJ, Frater AJ, et al. Adenovirus-mediated overexpression of extracellular superoxide dismutase improves endothelial dysfunction in a rat model of hypertension. Gene Ther. 2002;9: 110-117.
26. Miller WH, Brosnan MJ, Graham D, et al. Targeting endothelial cells with adenovirus expressing nitric oxide synthase prevents elevation of blood pressure in stroke-prone spontaneously hypertensive rats. Mol Ther. 2005; 12:321-327.
27. Kerr S, Brosnan MJ, McIntyre M, et al. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension. 1999;33:1353-1358.
28. Hamilton CA, Brosnan MJ, Al-Benna S, et al. NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension. 2002;40:755-762.
29. Graham D, Hamilton C, Beattie E, et al. Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. J Hypertens. 2004;22:329-337.
30. McBride MW, Brosnan MJ, Mathers J, et al. Reduction of Gstm1 expression in the stroke-prone spontaneously hypertension rat contributes to increased oxidative stress. Hypertension. 2005;45:786-792.
31. Dominiczak AF, McLaren Y, Kusel JR, et al. Lateral diffusion and fatty acid composition in vascular smooth muscle membrane from stroke-prone spontaneously hypertensive rats. Am J Hypertens. 1993;6:1003-1008.
32. Nicol CG, Denby L, Lopez-Franco O, et al. Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Lett. 2009;583:2100-2107.
33. Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lungtargeting peptide identified by in vivo phage display. J Biol Chem. 1999; 274:11593-11598.
34. Ruoslahti E, Rajotte D. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol. 2000;18: 813-827.
35. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A. 2002;99: 2252-2257.
36. Samoylova TI, Smith BF. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve. 1999;22:460-466.
37. Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10:625-632.
38. Nicklin SA, White SJ, Watkins SJ, et al. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation. 2000;102:231-237.
39. Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest. 1998;102:430-437.
40. Balestrieri ML, Napoli C. Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors. Eur J Cancer. 2007;43:1242-1250.
41. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22: 300-305.
42. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118.
43. White SJ, Nicklin SA, Buning H, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004;109:513-519.